Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® for Atopic Dermatitis and Epic...
12 April 2017 - 6:05PM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced it has
received two new regulatory approvals from the United Arab Emirates
Ministry of Health & Prevention.
The first approval, for Pediacyn® HydroGel (hypochlorous acid),
is intended for treatment of atopic dermatitis and other dermatoses
forming a protective barrier against physical, chemical and
microbial invasion of the atopic dermatitis lesions under the
supervision of a healthcare professional.
The second approval, for Epicyn® Scar Hydrogel (hypochlorous
acid), also under the supervision of a healthcare professional, is
intended for the management of scars by forming a protective
barrier against physical, chemical and microbial invasion of the
scar.
Both offerings, based upon Sonoma’s patented Microcyn®
Technology hypochlorous acid, will be supplied by MicroSafe Group
International to the UAE beginning in May 2017.
“The regulatory process in the United Arab Emirates is distinct
throughout Southwest Asia for being very thorough and rigorous.
Therefore, earning these two UAE approvals will certainly open the
path to growth and help to streamline regulatory approvals from
many other countries in the region,” said Safwan Abdallah,
MicroSafe group’s director of operations. “The first of these
two UAE approvals is for Pediacyn® HydroGel, an essential
non-steroidal treatment for all types of dermatitis and dermatoses,
which are common afflictions in our region due to severely humid
conditions. The second approval for Epicyn® Scar Hydrogel is
equally important. Epicyn® is intended to reduce the presence of
old and new hypertrophic and keloid scars, resulting from burns,
general surgical procedures and trauma wounds. Epicyn® can be used
immediately upon appearance of a wound or straight after suturing
of the wound. Access to these cutting edge advancements in
dermatology will satisfy a significant unmet need for physicians
across the UAE and increase the quality of life of patients’
suffering from these dermatological ailments.”
About Atopic DermatitisIn a 2015 study
published in the Annals of Nutrition & Metabolism, atopic
dermatitis is shown to be a chronic inflammatory skin disease
posing a significant burden on health-care resources and patients'
quality of life. A complex disease with a wide spectrum of clinical
presentations and combinations of symptoms, atopic dermatitis
affects up to 20% of children and up to 3% of adults; recent data
show that its prevalence is still increasing, especially in
low-income countries.
Scar Treatment MarketAccording to a P&S
Market Research report, the global scar treatment market accounted
for $15,944 billion in revenue in 2015, and it is expected to grow
at a CAGR of 10.0% during 2016-2022. The topical treatment segment
dominated the global market in 2015 with about 60.9% share. The
global scar treatment market is witnessing high growth rate, due to
growing cases with skin problems leading to scar formation,
availability of technologically advanced products, which have the
capability to fade away the scars and increasing appearance
consciousness among consumers. Also, the increasing expenditure on
personal care is further propelling the growth of the market.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies, the
Company may not meet its future capital needs, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission including its annual report on Form 10-K for
the fiscal year ended March 31, 2017. The Company disclaims
any obligation to update these forward-looking statements, except
as required by law.
Sonoma Pharmaceuticals®, Pediacyn®, Epicyn® and Microcyn® are
registered trademarks of Sonoma Pharmaceuticals, Inc. All
other trademarks and service marks are the property of their
respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024